Impact
urticaria
IRON DEFICIENCY ANEMIA, URTICARIA, ADVERSE EVENT, IRON DEFICIENCY ANEMIA IN CHILDREN

This study provided information on the pharmacokinetics and safety of intravenous ferric carboxymaltose for treatment of iron deficiency anemia in children and adolescents.In children aged 1–17 years with iron deficiency anemia, single intravenous doses of ferric carboxymaltose 7.5 or 15 mg/kg increased systemic exposure to iron in a dose-proportional manner, with clinically meaningful increases in hemoglobin.The most common drug-related treatment-emergent adverse event was urticaria.The findings suggest that iron deficiency anemia in children can be corrected with a single intravenous dose of ferric carboxymaltose and support use of a 15 mg/kg dose.